CCM
GSK icon

Cullen Capital Management’s GSK GSK Stock Holding History

Cullen Capital Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-46,619
Closed -$2.23M – 291
2021
Q3 		$2.23M Sell
46,619
-1,146
-2% -$57.6K 0.02% 151
2021
Q2 		$2.38M Sell
47,765
-124,869
-72% -$6M 0.02% 151
2021
Q1 		$7.7M Buy
172,634
+135,621
+366% +$6.16M 0.08% 103
2020
Q4 		$1.7M Buy
37,013
+2,525
+7% +$116K 0.09% 90
2020
Q3 		$1.62M Buy
34,488
+18,400
+114% +$922K 0.09% 87
2020
Q2 		$820K Hold
16,088
– – 0.05% 101
2020
Q1 		$762K Sell
16,088
-764
-5% -$40.8K 0.04% 97
2019
Q4 		$990K Sell
16,852
-4,272
-20% -$238K 0.04% 92
2019
Q3 		$1.13M Hold
21,124
– – 0.05% 91
2019
Q2 		$1.06M Buy
21,124
+7,840
+59% +$393K 0.04% 103
2019
Q1 		$694K Sell
13,284
-1,392
-9% -$69.6K 0.03% 103
2018
Q4 		$701K Hold
14,676
– – 0.03% 106
2018
Q3 		$737K Buy
14,676
+1,628
+12% +$82.7K 0.03% 107
2018
Q2 		$657K Buy
13,048
+28
+0.2% +$1.41K 0.02% 122
2018
Q1 		$636K Buy
13,020
+428
+3% +$19.9K 0.02% 124
2017
Q4 		$558K Hold
12,592
– – 0.02% 121
2017
Q3 		$639K Hold
12,592
– – 0.02% 120
2017
Q2 		$679K Sell
12,592
-34,104
-73% -$1.82M 0.02% 122
2017
Q1 		$2.46M Sell
46,696
-2,744
-6% -$139K 0.09% 98
2016
Q4 		$2.38M Sell
49,440
-2,720
-5% -$134K 0.08% 98
2016
Q3 		$2.81M Buy
52,160
+26,376
+102% +$1.45M 0.1% 95
2016
Q2 		$1.4M Sell
25,784
-72
-0.3% -$3.79K 0.05% 103
2016
Q1 		$1.31M Buy
25,856
+10,072
+64% +$502K 0.05% 104
2015
Q4 		$796K Buy
15,784
+1,384
+10% +$70.5K 0.03% 134
2015
Q3 		$692K Hold
14,400
– – 0.02% 137
2015
Q2 		$750K Buy
14,400
+9,000
+167% +$507K 0.02% 141
2015
Q1 		$312K Buy
5,400
+600
+13% +$34.4K 0.01% 155
2014
Q4 		$256K Buy
+4,800
New +$269K 0.01% 165

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Cullen Capital Management's GSK Position: Q4 2021 in Review

Cullen Capital Management sold out of GSK (GSK) in Q4 2021, closing a stake of 46,619 shares — an estimated $2.23M sold.

Cullen Capital Management first reported a position in GSK in Q4 2014 and held it in 28 quarters. The position peaked at $7.7M in Q1 2021. 919 funds tracked by Wall St. Rank hold GSK as of Q4 2021.

  • Cullen Capital Management reported no remaining GSK position as of Q4 2021 after selling out during the quarter.
  • Cullen Capital Management sold 46,619 GSK shares in Q4 2021, an estimated $2.23M.
  • Cullen Capital Management first reported a position in GSK in Q4 2014 and held it in 28 quarters.
  • Cullen Capital Management's GSK position peaked at $7.7M in Q1 2021.
  • 919 funds tracked by Wall St. Rank held GSK as of Q4 2021.

Based on Cullen Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.